Nasus Pharma NSRX 深 滬
等待開盤 09-17 09:30:00 美东时间
3.46
-0.130
-3.62%
華盛通- 最 高3.72
- 今 開3.64
- 成交量 1.09万股
- 最 低 3.41
- 昨 收 3.59
- 總市值 4051.94万
- 52周最高 9.50
- 市盈率 靜 --
- 換手率 0.09%
- 52周最低 1.98
- 委 比 -33.33%
- 總股本 1171.08万
- 歷史最高 9.9899
- 量 比 0.93
- 振 幅 8.64%
- 歷史最低 1.98
- 每 手 1
- 風險率 2.01%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Nasus Pharma Wins FDA Clearance to Begin NS002 Anaphylaxis Trial
Nasus Pharma Ltd. ( ($NSRX) ) has shared an announcement. On September 14, 2026...
09-14 20:47
Nasus Pharma Announces FDA Clearance to Initiate Clinical Study of NS002 in the Treatment of Anaphylaxis
Nasus Pharma announced FDA clearance for its IND application for NS002, an investigational intranasal epinephrine powder for treating anaphylaxis. NS002 aims to serve as a needle-free alternative to EpiPen®. The company plans to initiate a pivotal study in Q4 2026, with top-line data expected in Q1 2027. CEO Brendan O'Grady highlighted NS002's potential to address unmet needs in severe allergy treatment, offering faster onset and a non-invasive a...
09-14 12:00
Nasus Pharma CFO Eyal Rubin to leave
Nasus Pharma (NSRX) on Wednesday said Chief Financial Officer, Eyal Rubin will be leaving the company to pursue a new opportunity outside the life science industry. Rubin will remain with Nasus throu...
08-19 19:05
Nasus Pharma Announces Transition of Chief Financial Officer
Nasus Pharma Ltd. announced that Chief Financial Officer Eyal Rubin will leave the company to pursue a new opportunity outside the life sciences industry. Rubin will remain with the company until September 18, 2026, to ensure a smooth transition. Oren Elmaliach, Director of Finance, has been appointed Interim CFO. Elmaliach has been with Nasus since its inception and has over 15 years of financial experience, including working with public and pri...
08-19 11:00
Nasus Pharma 1H non-GAAP EPS of -$0.54
Nasus Pharma Ltd. press release (NSRX): 1H Non-GAAP EPS of -$0.54. Six months ended June 30, 2026, net loss totaled $5.94M. Research and development expenses increased to $2.59M while general and admi...
08-17 22:57
Nasus Pharma H1 EPS $(0.54) Misses $(0.20) Estimate
Nasus Pharma (AMEX:NSRX) reported quarterly losses of $(0.54) per share which missed the analyst consensus estimate of $(0.20) by 170 percent. This is a 217.65 percent decrease over losses of $(0.17) per share from the same period last year.
08-17 20:15
Nasus Pharma Appoints Brendan O'Grady As CEO, Succeeding Dan Teleman, Effective July 27
Nasus Pharma Ltd. (NYSE:NSRX) ("Nasus", "Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced the appointment of pharma industry veteran Brendan P. O'Grady as its Chief Executive Officer. Mr. O'Grady wi...
07-28 19:33
Nasus Pharma to Participate in the Zacks Life Sciences Investor Forum
Nasus Pharma Ltd. announced that its management will present at the Zacks Life Sciences Investor Forum on June 24-25, 2026. The virtual event will feature live, interactive sessions where investors can submit questions to management. Nasus Pharma, a clinical-stage company, is developing innovative intranasal powder products for acute medical conditions. Its NS002 product is a needle-free epinephrine option for anaphylaxis patients. The company’s ...
06-22 12:00
Nasus Pharma Announces NS003 Trial Demonstrates Preclinical Pharmacokinetic Profile Comparable To IV
Nasus Pharma Ltd. (NYSE:NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced positive results from a
06-09 20:02
Nasus Pharma Announces Positive Results from Preclinical Pharmacokinetic and Safety Study of Intranasal Ondansetron (NS003)
Nasus Pharma announced positive preclinical results for NS003, its intranasal powder formulation of ondansetron, showing comparable pharmacokinetics and safety to IV ondansetron in animal studies. The company plans to initiate a first-in-human PK study in Q3 2026, targeting unmet needs in chemotherapy and post-operative nausea and vomiting.
06-09 12:00
